Journal: Med (New York, N.Y.)

Article Title: Invariant Natural Killer T cells coordinate removal of senescent cells

doi: 10.1016/j.medj.2021.04.014

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Anti-iNKT Beads , Miltenyi Biotec, Inc. , 130-094-842.

Techniques: Purification, Recombinant, Lysis, Staining, cDNA Synthesis, Isolation, Selection, Enzyme-linked Immunosorbent Assay, Western Blot, Software

Journal: Frontiers in Molecular Biosciences

Article Title: Inflammatory status in pediatric sickle cell disease: Unravelling the role of immune cell subsets

doi: 10.3389/fmolb.2022.1075686

Figure Lengend Snippet: Differences in HLA-DR low monocytes, CD62L + neutrophils, NK lymphocytes, iNKT lymphocytes and CD34 + cells between sickle cell disease (SCD) patients and healthy donors (HD). * p ≤.05; ** p ≤.01; *** p ≤.001.

Article Snippet: Anti-CD3, anti-CD4, anti-CD8, anti-CD19, anti-CD16, anti-iNKT, anti-CD69, anti-HLA-DR, anti-CD56, anti-CD194, anti-CD196 and anti-CD33, anti-CD35, anti CD62P antibodies were purchased from Becton-Dickinson (Heidelberg, Germany), anti-CD25, anti-CD127, anti-CD45RA, anti-CCR7, anti-CD14, anti-CD45RA, anti-CD45RO, anti-CCR7, anti-CD62L and anti-CD183, anti-CD62L antibodies were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany), while anti-CD66b was purchased from Biolegend (San Diego, CA), anti-CCR10 were purchased from R&D System (Minneapolis, United States).

Techniques:

Journal: Frontiers in Molecular Biosciences

Article Title: Inflammatory status in pediatric sickle cell disease: Unravelling the role of immune cell subsets

doi: 10.3389/fmolb.2022.1075686

Figure Lengend Snippet: Main differences in the immunological profile (in percentage) between Sickle Cell Disease population and Healthy Donors. *Data with statistical significance.

Article Snippet: Anti-CD3, anti-CD4, anti-CD8, anti-CD19, anti-CD16, anti-iNKT, anti-CD69, anti-HLA-DR, anti-CD56, anti-CD194, anti-CD196 and anti-CD33, anti-CD35, anti CD62P antibodies were purchased from Becton-Dickinson (Heidelberg, Germany), anti-CD25, anti-CD127, anti-CD45RA, anti-CCR7, anti-CD14, anti-CD45RA, anti-CD45RO, anti-CCR7, anti-CD62L and anti-CD183, anti-CD62L antibodies were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany), while anti-CD66b was purchased from Biolegend (San Diego, CA), anti-CCR10 were purchased from R&D System (Minneapolis, United States).

Techniques:

Journal: Frontiers in Immunology

Article Title: Vaccine Designs Utilizing Invariant NKT-Licensed Antigen-Presenting Cells Provide NKT or T Cell Help for B Cell Responses

doi: 10.3389/fimmu.2018.01267

Figure Lengend Snippet: Induction of humoral immunity by utilizing iNKT-licensed B cells and iNKT-licensed dendritic cells (DCs). iNKT cells can provide both direct (A) and DC-mediated (B) help for antigen-specific B cell responses. (A) Innate iNKTfh cells recognize glycolipid antigen-CD1d on B cells and directly provide helper signals. These initiate plasmablast (PB) expansion and germinal center (GC) formation, leading to the primary class-switched antibody (Ab) production. (B) Antigen-expressing artificial adjuvant vector cells [e.g., artificial adjuvant vector cells (aAVC)-hemagglutinin (HA)] are comprised of the CD1d–α-GalCer complex on the surface of the aAVC and HA are expressed in the cytosol. (i) Administration of aAVC-HA initially stimulates iNKT cells. (ii) The aAVC-HA is killed by iNKT cells and NK cells and then HA tumor antigen released from them can be captured by endogenous CD11c + DCs. (iii) The CD11c + DCs then undergo iNKT cell-induced maturation. (iv) The activated DCs can then induce an HA-specific CD4 + T cell response. Thus, the CD11c + DCs in situ are able to present HA antigen derived from phagocytosed aAVC-HA to CD4 + T cells. (v) On the other hand, B cells also capture HA antigen. B cells can then be stimulated by antigen-specific CD4 + T cells, resulting in PB expansion, GC formation, and long-term Ab production.

Article Snippet: Simultaneously, the iNKT cell ligand from the immunogen is loaded on CD1d inside of B cells and then expressed on the cell surface, resulting in a strong cognate iNKT–B cell interaction ( – ) (Figure A).

Techniques: Expressing, Adjuvant, Plasmid Preparation, In Situ, Derivative Assay